Gefitinib

證據等級: L5

預測適應症: 10 個

Gefitinib: From Non-Small Cell Lung Cancer to Fibromatosis, Gingival

One-Sentence Summary

Gefitinib is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, established in the treatment of non-small cell lung cancer (NSCLC) — this original-use context is drawn from literature contained in this evidence pack, as no formal regulatory license data is available. The TxGNN model predicts it may be effective for Fibromatosis, Gingival, but this direction is currently supported by 0 clinical trials and 0 publications — it is a pure model prediction with no corroborating evidence.

Quick Overview

Item	Content
Original Indication	Non-Small Cell Lung Cancer (NSCLC) — inferred from literature within this evidence pack; no formal regulatory indication text available (drug not licensed locally)
Predicted New Indication	Fibromatosis, Gingival
TxGNN Prediction Score	99.89%
Evidence Level	L5
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on information available within this evidence pack's literature (e.g., PMID 24794908, PMID 12841190), gefitinib is a selective, orally active small-molecule inhibitor of the EGFR tyrosine kinase, and its efficacy in EGFR-mutation-driven non-small cell lung cancer has been well established.

Gingival fibromatosis is a fibroblast-proliferative disorder of the gum tissue, unrelated in histology or driver biology to EGFR-mutant NSCLC. The repurposing rationale offered for this pair is purely theoretical: EGFR signalling is broadly implicated in fibroproliferative processes in general, so a mechanistic link to fibrotic gingival overgrowth is conceivable in principle.

However, this connection has not been tested or reported anywhere in the literature or clinical trial registries queried for this pair. The prediction rests entirely on the TxGNN knowledge-graph model's score, with no experimental, case-level, or clinical corroboration — this is why the evidence level is rated L5 and the decision stage is S0.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is supported only by the TxGNN model score, with zero clinical trials and zero literature records for the drug–indication pair — evidence level L5, decision stage S0. No mechanism-of-action, regulatory, or safety data are currently available to support progression.

To proceed, the following is needed:

Mechanism of action (MOA) data from DrugBank to substantiate the EGFR-fibrosis mechanistic hypothesis
Preclinical or case-level evidence specifically linking gefitinib to gingival fibromatosis or fibroproliferative gum disease
TFDA/regulatory package insert (warnings, contraindications, drug interactions) to complete a baseline safety assessment
Confirmation of local market/licensing status, since the drug is currently not marketed in the target jurisdiction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.